Recently, Meisel and colleagues [48] explored the GM-CSF therapy versus placebo in sepsis, the first mHLA-DR-guided immunostimulatory treatment, indicating that administration of GM-CSF to patients in the immunosuppressive phase of sepsis reversed the characteristic monocyte deactivation as demonstrated by an increase in mHLA-DR levels and Toll-like receptor-4- and Toll-like receptor-2-induced cytokine production, and reduced time of mechanical ventilation as well as length of hospital and intensive care unit stay. This evidence concerns the gene CSF2 and Sepsis.